



UNICHEM
LABORATORIES LTD.

May 29, 2019

The Corporate Relationship Dept.
BSE Limited
1st Floor, P.J.Towers
Rotunda Building
Dalal Street, Fort
Mumbai - 400 001

The Manager
Listing Dept.
The National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor,
Bandra-Kurla Complex, Bandra (E)
Mumbai - 400 051

Dear Sir,

Ref: BSE Scrip Code -506690: NSE Symbol – UNICHEMLAB

Sub.: Compliance Under Regulation 47 of the SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 ('Listing Regulations')

Dear Sir/Madam,

Pursuant to Regulation 47 of the Listing Regulations, please find enclosed copy of financial results of the Company for the quarter and year ended March 31, 2019 published in the following newspapers on May 25, 2019.

1. Mumbai edition of Business Standard
2. Mumbai edition of Sakal

Kindly take the same on your records.

Thanking you,
FOR UNICHEM LABORATORIES LIMITED

Neema Thakore
Head- Legal & Company Secretary
Encl: a/a



**UNICHEM
LABORATORIES LTD.**

CIN :L99999MH1962PLC012451

Regd. Office: Unichem Bhavan, Prabhat Estate, SV. Road, Jogeshwari (West), Mumbai - 400 102

Tel. No.: 91 (22) 6688 8333 • Fax. No.: 91 (22) 2678 4391

Website: www.unichemlabs.com • E-mail ID.: shares@unichemlabs.com

EXTRACT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER & AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED 31ST MARCH, 2019.

₹ Lakhs

Particulars	Standalone				Consolidated		
	Quarter ended 31st Mar'19 (Unaudited)	Quarter ended 31st Dec'18 (Unaudited)	Quarter ended 31st Mar'18 (Audited)	Year ended 31st Mar'19 (Audited)	Year ended 31st Mar'18 (Audited)	Year ended 31st Mar'19 (Audited)	Year ended 31st Mar'18 (Audited)
1 Total income (excluding other income) from continuing operations	27,708.14	24,436.12	20,344.28	96,773.89	66,646.97	118,004.68	81,498.48
2 Profit / (loss) before tax from continuing operations	(38.24)	(901.90)	617.55	(2,158.02)	(12,155.04)	(5,990.53)	(12,975.55)
3 Profit / (loss) before tax from discontinued operations (Refer note 2)	974.25	(367.94)	229.13	246.96	337,089.17	246.96	337,089.17
4 Profit / (loss) for the period from continuing operations after tax	369.28	632.05	280.45	704.20	(12,140.95)	(2,555.76)	(13,309.77)
5 Profit / (loss) for the period from discontinued operations after tax	625.01	(201.94)	(55.70)	175.72	267,800.80	175.72	267,800.80
6 Total Comprehensive Income for the period [Comprising of Profit/(Loss) for the period (after tax) and other comprehensive income (after tax)]	972.52	357.78	120.22	851.43	255,479.77	(2,193.07)	254,032.40
7 Paid-up Equity Share Capital	1,407.67	1,407.67	1,406.74	1,407.67	1,406.74	1,407.67	1,406.74
8 Other Equity [Reserves excluding Revaluation Reserve]				271,785.74	274,759.86	260,583.02	266,601.64
9 Earnings per share (of ₹ 2/- each) from continuing operations and discontinued operations (in ₹)							
(a) Basic	1.41	0.61	0.25	1.25	281.88	(3.38)	280.60
(b) Diluted	1.41	0.61	0.25	1.25	281.70	(3.38)	280.41

Notes:

- The standalone financial results for the quarter and year ended 31st March, 2019 and consolidated financial results for the year ended 31st March 2019 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at its meeting held on 24th May, 2019. The statutory auditors have expressed an unqualified audit opinion on these standalone and consolidated financial results. The above is an extract of the detailed format of the standalone and consolidated financial results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of these standalone and consolidated financial results are available on the websites of the Stock Exchanges i.e. www.bseindia.com and www.nseindia.com and the Company at www.unichemlabs.com.
- During the year ended 31st March 2018, based on the approval obtained from the Shareholders, the Company had transferred its business of manufacture, sale, marketing and distribution of domestic formulations in India and Nepal ("Identified Business") by way of slump sale on going concern basis to Torrent Pharmaceuticals Limited ("Torrent"). Identified business includes portfolio of several brands in India and Nepal, manufacturing facility at Sikkim and employees performing work in relation to said business. Gain on sale of Identified Business (net) amounting to ₹ 321,731.05 lakhs had been recognised and disclosed under discontinued operations in the above results.
- The Board recommends a final dividend of ₹ 41- per share (200 %) (face value of ₹ 2/- per share) for the year ended 31st March, 2019. The payment is subject to the approval of the shareholders in the ensuing Annual General Meeting of the Company.

By Order of the Board
For **Unichem Laboratories Limited**
Sd/-

Dr. Prakash A. Wody
Chairman & Managing Director
DIN: 00001285

Place: Mumbai
Date: 24th May, 2019



मुंबई, शनिवार,
२५ मे २०१९



UNICHEM LABORATORIES LTD.

CIN :L99999MH1962PLC012451

Regd. Office: Unichem Bhavan, Prabhat Estate, S.V. Road, Jogeshwari (West), Mumbai - 400 102

Tel. No.: 91 (22) 6688 8333 • Fax. No.: 91 (22) 2678 4391

Website: www.unichemlabs.com • E-mail ID: shares@unichemlabs.com

EXTRACT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER & AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED 31ST MARCH, 2019.

₹ Lakhs

Particulars	Standalone				Consolidated		
	Quarter ended 31st Mar'19 (Unaudited)	Quarter ended 31st Dec'18 (Unaudited)	Quarter ended 31st Mar'18 (Audited)	Year ended 31st Mar'19 (Audited)	Year ended 31st Mar'18 (Audited)	Year ended 31st Mar'19 (Audited)	Year ended 31st Mar'18 (Audited)
	1 Total income (excluding other income) from continuing operations	27,708.14	24,436.12	20,344.28	96,773.89	66,646.97	118,004.68
2 Profit / (loss) before tax from continuing operations	(38.24)	(901.90)	617.55	(2,158.02)	(12,155.04)	(5,990.53)	(12,975.55)
3 Profit / (loss) before tax from discontinued operations (Refer note 2)	974.25	(367.94)	229.13	246.96	337,089.17	246.96	337,089.17
4 Profit / (loss) for the period from continuing operations after tax	369.28	632.05	280.45	704.20	(12,140.95)	(2,555.76)	(13,309.77)
5 Profit / (loss) for the period from discontinued operations after tax	625.01	(201.94)	(55.70)	175.72	267,800.80	175.72	267,800.80
6 Total Comprehensive Income for the period [Comprising of Profit/(Loss) for the period (after tax) and other comprehensive income (after tax)]	972.52	357.78	120.22	851.43	255,479.77	(2,193.07)	254,032.40
7 Paid-up Equity Share Capital	1,407.67	1,407.67	1,406.74	1,407.67	1,406.74	1,407.67	1,406.74
8 Other Equity [Reserves excluding Revaluation Reserve]				271,785.74	274,759.86	260,583.02	266,601.64
9 Earnings per share (of ₹ 2/- each) from continuing operations and discontinued operations (in ₹)							
(a) Basic	1.41	0.61	0.25	1.25	281.88	(3.38)	280.60
(b) Diluted	1.41	0.61	0.25	1.25	281.70	(3.38)	280.41

Notes:

- The standalone financial results for the quarter and year ended 31st March, 2019 and consolidated financial results for the year ended 31st March 2019 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at its meeting held on 24th May, 2019. The statutory auditors have expressed an unqualified audit opinion on these standalone and consolidated financial results. The above is an extract of the detailed format of the standalone and consolidated financial results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of these standalone and consolidated financial results are available on the websites of the Stock Exchanges i.e. www.bseindia.com and www.ns&india.com and the Company at www.unichemlabs.com.
- During the year ended 31st March 2018, based on the approval obtained from the Shareholders, the Company had transferred its business of manufacture, sale, marketing and distribution of domestic formulations in India and Nepal ("Identified Business") by way of slump sale on going concern basis to Torrent Pharmaceuticals Limited ("Torrent"). Identified business includes portfolio of several brands in India and Nepal, manufacturing facility at Sikkim and employees performing work in relation to said business. Gain on sale of Identified Business (net) amounting to ₹ 321,731.05 lakhs had been recognised and disclosed under discontinued operations in the above results.
- The Board recommends a final dividend of ₹ 4/- per share (200%) (face value of ₹ 2/- per share) for the year ended 31st March, 2019. The payment is subject to the approval of the shareholders in the ensuing Annual General Meeting of the Company.

By Order of the Board
For Unichem Laboratories Limited
Sd/-

Dr. Prakash A. Mody
Chairman & Managing Director
DIN: 00001285

Place: Mumbai
Date: 24th May, 2019